

Ana P Castano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4891896/publications.pdf>

Version: 2024-02-01

17
papers

6,108
citations

687363

13
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

8770
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract 556: Novel anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. <i>Cancer Research</i> , 2022, 82, 556-556.	0.9	4
2	Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	132
3	A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. <i>Molecular Therapy</i> , 2020, 28, 2577-2592.	8.2	58
4	Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. <i>Journal of Biological Chemistry</i> , 2019, 294, 18465-18474.	3.4	35
5	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Advances</i> , 2019, 3, 3248-3260.	5.2	76
6	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. <i>Clinical Cancer Research</i> , 2019, 25, 7046-7057.	7.0	56
7	Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 4443-4443.	1.4	6
8	Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors. <i>Blood</i> , 2019, 134, 866-866.	1.4	0
9	Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. <i>Nature Biotechnology</i> , 2018, 36, 707-716.	17.5	448
10	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. <i>Blood</i> , 2018, 132, 1495-1506.	1.4	100
11	Overcoming a Critical Obstacle Towards Effective and Safe CAR T-Cell Therapeutics. <i>Blood</i> , 2018, 132, 2056-2056.	1.4	0
12	Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5495-5500.	7.1	193
13	Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time. <i>Lasers in Surgery and Medicine</i> , 2007, 39, 543-550.	2.1	122
14	Photodynamic therapy and anti-tumour immunity. <i>Nature Reviews Cancer</i> , 2006, 6, 535-545.	28.4	2,232
15	Mechanisms in photodynamic therapy: part two—cellular signaling, cell metabolism and modes of cell death. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 1-23.	2.6	586
16	Mechanisms in photodynamic therapy: Part three—Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 91-106.	2.6	437
17	Mechanisms in photodynamic therapy: part one—photosensitizers, photochemistry and cellular localization. <i>Photodiagnosis and Photodynamic Therapy</i> , 2004, 1, 279-293.	2.6	1,623